MedTrace Logo

Botswana TDF/FTC Oral HIV Prophylaxis Trial

NCT00448669 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1219

Last updated 2020-02-05

Study results available
· View outcomes & findings →

Summary

This study tested whether taking a pill of tenofovir and emtricitabine (two antiretroviral medicines) was safe for sexually-active young adults in Botswana without HIV infection and whether it reduced their risk of getting an HIV infection.

Conditions

  • HIV Infections

Interventions

DRUG

Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg

DRUG

Placebo Oral Tablet

Sponsors & Collaborators

Principal Investigators

  • Michael Thigpen, MD MPH · National Institutes of Health (NIH)

  • Lynn Paxton, MD MPH · Centers for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States
  • Botswana

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00448669 on ClinicalTrials.gov